key: cord-0859770-3qof92dn
authors: Khan, Jaffar M.; Khalid, Nauman; Shlofmitz, Evan; Forrestal, Brian J.; Yerasi, Charan; Case, Brian C.; Chezar-Azerrad, Chava; Musallam, Anees; Rogers, Toby; Waksman, Ron
title: Guidelines for balancing priorities in structural heart disease during the COVID-19 pandemic
date: 2020-05-30
journal: Cardiovasc Revasc Med
DOI: 10.1016/j.carrev.2020.05.040
sha: ec6b6d4db29297f4082f17f019d40ab8b4b1a80a
doc_id: 859770
cord_uid: 3qof92dn

During the novel coronavirus disease 2019 (COVID-19) pandemic, many hospitals have been asked to postpone elective and surgical cases. This begs the question, “What is elective in structural heart disease intervention?” The recently proposed Society for Cardiovascular Angiography and Interventions/American College of Cardiology consensus statement is, unfortunately, non-specific and insufficient in its scope and scale of response to the COVID-19 pandemic. We propose guidelines that are practical, multidisciplinary, implementable, and urgent. We believe that this will provide a helpful framework for our colleagues to manage their practice during the surge and peak phases of the pandemic. General principles that apply across structural heart disease interventions include tracking and reporting cardiovascular outcomes, “healthcare distancing,” preserving vital resources and personnel, shared decision-making between the heart team and hospital administration on resource-intensive cases, and considering delaying research cases. Specific guidance for transcatheter aortic valve replacement and MitraClip procedures varies according to pandemic phase. During the surge phase, treatment should broadly be limited to those at increased risk of complications in the near term. During the peak phase, treatment should be limited to inpatients for whom it may facilitate discharge. Keeping our patients and ourselves safe is paramount, as well as justly rationing resources.

During the global novel coronavirus disease 2019 (COVID-19) pandemic, resources are being redirected toward treating patients infected with the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) virus. In order to meet the challenges of the pandemic, hospitals have been directed to cease elective work, especially elective surgeries that utilize valuable ventilators and occupy intensive care unit (ICU) beds. Structural heart disease interventions, particularly transcatheter aortic valve replacement (TAVR) for symptomatic severe aortic stenosis (AS) and transcatheter mitral valve repair with a MitraClip In a consensus statement from the Society for Cardiovascular Angiography and Interventions (SCAI) and

the American College of Cardiology (ACC), the authors proposed performing TAVR to treat symptomatic severe AS in all inpatients if they had reduced EF secondary to AS, New York Heart Association (NYHA) J o u r n a l P r e -p r o o f 5 class III/IV heart failure secondary to AS, or syncope secondary to AS [2] . The authors recommended treating outpatients with severe to critical AS if they had syncope due to NYHA class III/IV heart failure.

Treatment could be considered in minimally symptomatic patients with echocardiographic measures consistent with very severe AS based on gradient and valve area. The authors recommended deferring treatment in asymptomatic patients with severe to critical AS but urged weekly remote check-in.

Whereas the CAIC proposes a major scaling down of operations in a time-sensitive manner, the SCAI/ACC statement recommends treatment in a larger cohort of patients and voices comfort with deferring treatment only in asymptomatic patients. Many practical details for the heart team, the operators, and the hospital administration are understandably missing.

We recognize that this is an evolving situation in which guidelines need to be flexible and hospitals need to be nimble. The guidelines proposed in this manuscript attempt to provide cohesive guidance for structural heart disease treatment in the United States given our current knowledge of the COVID-19 pandemic and keeping in mind patient and healthcare safety and resource allocation ( 

Symptomatic severe AS carries an abysmal prognosis, with a 1-to 2-year mortality rate of 50% [3] . The patients who do worse when treated conservatively are those older than 80 years of age with chronic kidney disease, heart failure, EF <40%, pulmonary artery systolic pressure >60 mmHg, and moderate or severe MR [4] . Information on patient outcomes during wait times for TAVR has been accrued from Ontario, where the mean wait time was 80 days from diagnosis to TAVR. These patients had a mortality rate of 2% and a heart failure admission rate of 12% at 80 days [5] . 18. TAVR should be preferred over surgical aortic valve replacement because of the decreased length of stay and valuable resource utilization. 19. Regional centers for TAVR should be established during the "surge phase" of the pandemic, taking into consideration geographic coverage and center TAVR volumes. This would enable streamlined services for patients who need them while freeing up peripheral hospitals to deal with the pandemic. Criteria for regional centers should be established by CMS using principles of just allocation of resources and patient access to care.

Many of the principles that apply to TAVR also apply to transcatheter mitral valve repair with the MitraClip. A few specific points are mentioned below.

1. Patients with increased risk of complications in the near term, particularly with repeated admissions for heart failure secondary to severe or moderate-to-severe primary MR that can be treated with a MitraClip, should be treated during the surge phase of the pandemic.

2. During the pandemic peak, inpatients with heart failure secondary to severe primary MR should be offered MitraClip therapy when it will expedite hospital discharge.

3. These procedures require transesophageal echocardiography (TEE), ventilator use, and an J o u r n a l P r e -p r o o f

Precautions and Procedures for Coronary and Structural Cardiac Interventions during the COVID-19 Pandemic: Guidance from Canadian Association of Interventional Cardiology

Triage Considerations for Patients Referred for Structural Heart Disease Intervention During the Coronavirus Disease 2019 (COVID-19) Pandemic: An ACC /SCAI Consensus Statement

Aortic stenosis

nonsurgically managed patients with severe aortic stenosis

Temporal Trends and Clinical Consequences of Wait Times for Transcatheter Aortic Valve Replacement: A Population-Based Study

Outcomes of transcatheter aortic valve replacement using a minimalist approach

Predictors and Clinical Outcomes of Next-Day Discharge After Minimalist Transfemoral Transcatheter Aortic Valve Replacement

Factors associated with length of stay following trans-catheter aortic valve replacement -a multicenter study